Mitesh Borad, MD
Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mitesh Borad, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:31 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03377179 · A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced CholangiocarcinomaRedHill Biopharma Limited · completed · Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar · principal investigator
- Ph2NCT01144455 · Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic AdenocarcinomaImmunoGenesis · completed · Pancreatic Adenocarcinoma · principal investigator
- Ph1/Ph2NCT00743379 · Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid TumorsThreshold Pharmaceuticals · completed · Non-Small Cell Lung Cancer, Prostate Cancer, Pancreatic Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.